X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement provides Provectus with the University’s PDAT medical device in combination with a formulation of the Company’s proprietary pharmaceutical-grade RB-PDT (rose bengal sodium), for treating bacterial, fungal, and parasitic (acanthamoeba) infections of the eye.
Lead Product(s): Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area: Infections and Infectious Diseases Product Name: RB-PDT
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: University of Miami
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 27, 2024
Details:
PV-10 (rose bengal sodium) Percutaneous intralesional injection, which is investigated in combination with standard of care immune checkpoint blockade (CB) for the treatment of advanced cutaneous melanoma.
Lead Product(s): Rose Bengal Sodium,Pembrolizumab
Therapeutic Area: Oncology Product Name: PV-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
PV-10 (rose bengal sodium) Percutaneous intralesional injection, which is investigated in combination with standard of care immune checkpoint blockade (CB) for the treatment of Metastatic Uveal Melanoma.
Lead Product(s): Rose Bengal Disodium,Pembrolizumab
Therapeutic Area: Oncology Product Name: PV-10
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Intralesional (IL) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death within hours of tumor injection, and induce tumor-specific reactivity in circulating T cells within days.
Lead Product(s): Rose Bengal Sodium,Pembrolizumab
Therapeutic Area: Oncology Product Name: PV-10
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
Intralesional (IL) (aka intratumoral) administration of PV-10 for the treatment of solid tumor cancers can yield immunogenic cell death and induce tumor-specific reactivity in circulating T cells.
Lead Product(s): Rose Bengal Sodium,Pembrolizumab
Therapeutic Area: Oncology Product Name: PV-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Provectus' Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10 in combination with KEYTRUDA for the treatment of advanced cutaneous melanoma in patients naive to immune checkpoint blockade will be presented at the European Society for Medical Oncology.
Lead Product(s): Rose Bengal Sodium,Pembrolizumab
Therapeutic Area: Oncology Product Name: PV-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Presentation highlights clinical trial of PV-10 as a single-agent and in combination with immune checkpoint blockade for the treatment of primary or metastatic tumors of the liver.
Lead Product(s): Rose Bengal Sodium,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
